Sesen Bio Stock News

Healthcare > Biotechnology

Buy SESN

*Your capital is at risk

$0.629

+0 (+0%)

At Close: Jun 06, 2023

Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™ Accepted for Review by the National Medical Products Administration in China

08:00am, Wednesday, 13'th Jan 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported tha

Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review

08:00am, Monday, 21'st Dec 2020

Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum™ Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER)

08:00am, Friday, 18'th Dec 2020

Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa

08:00am, Tuesday, 01'st Dec 2020

Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript

11:12am, Monday, 09'th Nov 2020

Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript

Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript

08:47am, Monday, 09'th Nov 2020

Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by